Facts & Figures

Facts - Grünenthal Group worldwide

Year of Foundation: 1946

Shareholder Structure 2012: 19 shareholders

Group Operating Committee:

Corporate Officers:

  • Harald F. Stock, PhD., Chief Executive Officer, Chairman of the Corporate Management Board
  • Prof. Dr. Eric-Paul Pâques, President Grünenthal Innovation & Chief Alliance Officer, Vice-Chairman of the Corporate Management Board
  • Stefan Genten, Chief Financial Officer & Chief Operating Office

Heads of the Strategic Business Units and Functions:

  • Oscar Ferenczi Executive Vice President Grünenthal Latin America
  • Alberto Grua, PhD., Executive Vice President Grünenthal Europe & Australia
  • Klaus D. Langner, PhD., Executive Executive Vice President and Chief Operating Officer of Grünenthal Innovation
  • Dieter Peters, PhD., Executive Vice President Global Product Supply
  • Thomas Senderovitz, M.D., Executive Vice President Compound Development & Branding
  • Heinz-Gerd Suelmann, PhD., Executive Vice President Global Human Resources

Supervisory Board 2012: 5 members

International Presence 2012: 26 Countries with affiliates in Europe, Australia, Latin America and USA, Production sites in 5 countries, headquarters Aachen, Germany

Main Business Areas 2012: Pain

Top-Selling Products (Global Brands 2012):  Palexia®, Zaldiar®, Tramal®, Transtec®, Norspan®, Versatis®, INTAC®

Corporate Figures - Year 2011 & 2012

Corporate Figures in Mio € 2012 2011
Revenues 973 947
   Revenue Growth vs. Previous Year 3% 4%
   Growth Pain Business Europe&Australia (acc. to IMS, %) + 25% + 19%
   Growth Latin America (acc. to IMS, %) + 9% + 14%
Revenues by regions             973             947
   Europe 610 673
   Latin America 199 141
   USA 135 111
   Rest of world 29 22
Revenues by product 973 947
     Palexia®  67  31
     Versatis® 96 68
     Zaldiar ® (incl. Ixprim®) 166 176
     Transtec® 80 90
     Norspan® 26 24
     Tramal® 114 134
     Nucynta®1  20  15
     INTAC®2 80 50
     Others 324 359
Research & Development Costs 251 233
    R&D Costs Ratio (R&D Costs / Revenues) 26% 25%
Operating EBITA 79 5
    Operating EBITA / Revenues (%) 8% 0%
Income before Taxes (IBT) 228 127
   Income before Taxes / Revenues (%) 23% 13%
Equity Ratio (%) 70% 64%
Employees (annual average, headcount) ca. 4,400 ca. 4,700

Our financial statements are published at www.ebundesanzeiger.de (German)
1 Revenues from licenses
2 Revenues from licenses and net operating sales